Skip to main navigation Skip to search Skip to main content

Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging

  • Yaqi Tian
  • , Hongliang Shen
  • , Lingbing Li
  • , Xiaohua Jia
  • , Jin Liu
  • , Zhenhua Hu*
  • , Liang Wang*
  • , Jie Tian*
  • *Corresponding author for this work
  • Capital Medical University
  • CAS - Institute of Automation
  • General Hospital of People's Liberation Army
  • National Key Laboratory of Kidney Diseases

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: One of the main reasons for prostate cancer (PCa) recurrence is the difficulty in identifying and removing cancerous lesions during surgery. Accurately localizing and excising cancerous tissue remains a significant challenge. The second near-infrared window (NIR-II, 1000–1700 nm) fluorescence offers enhanced resolution, a high signal-to-noise ratio, and the potential for deeper tissue penetration. However, this technology is not currently employed for intraoperative imaging of PCa. This study aims to construct a new NIR-II probe targeting B7-H3 (AbB7−H3-800CW) for accurate intraoperative identification and resection of PCa. Methods: Based on the differential expression of B7-H3 in PCa, we designed a novel imaging probe to accurately identify and guide the resection of preclinical PCa models and ex vivo human PCa tissues using NIR-II fluorescence imaging technology. Results: Analyzing tissue samples from 60 clinical cases of PCa, along with benign prostatic hyperplasia and normal prostate tissue from 22 cases, we observed a significant difference in B7-H3 protein expression levels (P < 0.001). Subcutaneous and orthotopic mouse models of PCa were imaged using NIR-II fluorescence after AbB7−H3-800CW injection, showing promising results with successful tumor targeting and high-contrast images achieved within 24–48 h post-injection. The imaging also enabled the detection of occult PCa lesions approximately 1 mm in diameter. In addition, imaging analysis of human PCa and adjacent tissues using AbB7−H3-800CW incubation revealed that cancer tissues exhibited a significantly higher fluorescence intensity than adjacent tissues (P < 0.05), which was conducive to the evaluation of tumor resection margin in vitro. Conclusion: The findings revealed that B7-H3 was a compelling imaging target for PCa. The AbB7−H3-800CW molecular imaging probe is capable of accurately identifying PCa lesions and guiding their removal. This approach can potentially reduce the rate of surgical margins under NIR-II fluorescence guidance.

Original languageEnglish
Pages (from-to)2569-2582
Number of pages14
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume51
Issue number9
DOIs
StatePublished - Jul 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Fluorescence
  • Molecular imaging
  • Prostate cancer
  • Second near-infrared window
  • Surgery

Fingerprint

Dive into the research topics of 'Enhancing surgical outcomes: accurate identification and removal of prostate cancer with B7-H3-targeted NIR-II molecular imaging'. Together they form a unique fingerprint.

Cite this